Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H32O4 |
| Molecular Weight | 396.5192 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H](\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/C3=CC(=CC=C3)C(O)=O)C4CCCCC4
InChI
InChIKey=OINUMRGCICIETD-CGKNXJIZSA-N
InChI=1S/C25H32O4/c26-23(18-6-2-1-3-7-18)10-9-21-22-14-17(13-20(22)15-24(21)27)11-16-5-4-8-19(12-16)25(28)29/h4-5,8-12,18,20-24,26-27H,1-3,6-7,13-15H2,(H,28,29)/b10-9+,17-11+/t20-,21+,22-,23+,24+/m0/s1
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antithrombotic effects of the prostacyclin analogue naxaprostene after oral and intraduodenal application in rabbit carotid artery thrombosis. | 1992 |
|
| Influence on platelet activity and red cell fluidity of epoprostenol and two stable prostacyclin analogues in vitro. | 1986-08 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1632291
The antithrombotic efficacy of naxaprostene has been tested in rabbits with copper coil-induced carotid artery thrombosis. With oral pretreatment, 10 mg/kg naxaprostene prevented thrombotic arterial occlusion; with intraduodenal pretreatment the efficacy of naxaprostene was enhanced and 1 mg/kg was sufficient to exert an antithrombotic effect.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3096342
ADP-induced aggregation is inhibited 25% by 50 nmol/l CG 4305 (naxaprostene).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C78568
Created by
admin on Mon Mar 31 18:20:09 GMT 2025 , Edited by admin on Mon Mar 31 18:20:09 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6QS1XD4508
Created by
admin on Mon Mar 31 18:20:09 GMT 2025 , Edited by admin on Mon Mar 31 18:20:09 GMT 2025
|
PRIMARY | |||
|
SUB09172MIG
Created by
admin on Mon Mar 31 18:20:09 GMT 2025 , Edited by admin on Mon Mar 31 18:20:09 GMT 2025
|
PRIMARY | |||
|
100000080344
Created by
admin on Mon Mar 31 18:20:09 GMT 2025 , Edited by admin on Mon Mar 31 18:20:09 GMT 2025
|
PRIMARY | |||
|
C87383
Created by
admin on Mon Mar 31 18:20:09 GMT 2025 , Edited by admin on Mon Mar 31 18:20:09 GMT 2025
|
PRIMARY | |||
|
6446653
Created by
admin on Mon Mar 31 18:20:09 GMT 2025 , Edited by admin on Mon Mar 31 18:20:09 GMT 2025
|
PRIMARY | |||
|
DTXSID301024705
Created by
admin on Mon Mar 31 18:20:09 GMT 2025 , Edited by admin on Mon Mar 31 18:20:09 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105172
Created by
admin on Mon Mar 31 18:20:09 GMT 2025 , Edited by admin on Mon Mar 31 18:20:09 GMT 2025
|
PRIMARY | |||
|
87269-59-8
Created by
admin on Mon Mar 31 18:20:09 GMT 2025 , Edited by admin on Mon Mar 31 18:20:09 GMT 2025
|
PRIMARY | |||
|
6189
Created by
admin on Mon Mar 31 18:20:09 GMT 2025 , Edited by admin on Mon Mar 31 18:20:09 GMT 2025
|
PRIMARY | |||
|
C050548
Created by
admin on Mon Mar 31 18:20:09 GMT 2025 , Edited by admin on Mon Mar 31 18:20:09 GMT 2025
|
PRIMARY |
ACTIVE MOIETY